Compare AIN & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AIN | FTRE |
|---|---|---|
| Founded | 1895 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Textiles | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.5B |
| IPO Year | 1987 | N/A |
| Metric | AIN | FTRE |
|---|---|---|
| Price | $56.79 | $15.61 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $60.25 | $15.50 |
| AVG Volume (30 Days) | 286.8K | ★ 1.3M |
| Earning Date | 02-25-2026 | 02-26-2026 |
| Dividend Yield | ★ 1.99% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,148,512,000.00 | ★ $2,759,900,000.00 |
| Revenue This Year | N/A | $3.21 |
| Revenue Next Year | N/A | $0.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 1.88 |
| 52 Week Low | $41.15 | $3.97 |
| 52 Week High | $83.65 | $18.67 |
| Indicator | AIN | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 55.23 | 43.25 |
| Support Level | $54.61 | $15.49 |
| Resistance Level | $57.21 | $17.20 |
| Average True Range (ATR) | 1.52 | 1.07 |
| MACD | -0.35 | -0.21 |
| Stochastic Oscillator | 38.36 | 16.19 |
Albany International Corp is principally engaged in processing textiles and materials. The company consists of two business segments, the machine clothing segment, which produces and provides custom-designed fabrics and belts for the production in the paper, nonwovens, and other process industries; and the Albany engineered composites segment, which offers engineered composite parts for the aerospace and defensive industries. The machine clothing segment contributes to the majority of the company's total revenue. The company has an operation and generates revenue from the United States, Switzerland, Brazil, China, Mexico, France, and other areas.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion. Fortrea has 19,000 staff members across 90 countries.